What can be learned from the Dengue Vaccine Controversy?  a. All vaccines have harmful effects and should not be trusted. b. Taking vaccines should be voluntary and side effects should be explained to the recipient or doctors at least. c. Vaccines on their early development should be taken with great precaution. d. Vaccines are deadly.

An Illustrated Guide To Vet Med Term
4th Edition
ISBN:9781305465763
Author:ROMICH
Publisher:ROMICH
Chapter16: Testing Testing
Section: Chapter Questions
Problem 1M
icon
Related questions
Question
100%

What can be learned from the Dengue Vaccine Controversy? 


a. All vaccines have harmful effects and should not be trusted.
b. Taking vaccines should be voluntary and side effects should be explained to the recipient or doctors at least.
c. Vaccines on their early development should be taken with great precaution.
d. Vaccines are deadly.

Terms:
Seronegative: Individuals who had never been infected by dengue virus.
Fact 1: The program on the study for the production of dengue vaccine started in 1920. Vaccines are
usually produced with minimum of 5 years of clinical trials.
Fact 2: Dengvaxia, a dengue vaccine produced by Sanofi Pharmaceuticals, became commercially
available in 2015 and 2016, in 11 countries: Mexico, the Philippines, Indonesia, Brazil, El Salvador, Costa
Rica, Paraguay, Guatemala, Peru, Thailand, and Singapore.
Fact 3: Trade named Dengvaxia, it is approved for use for those aged nine and older and can prevent
all four serotypes resulting from high efficacy rate in its trial use.
Fact 4: In 2017, the manufacturer recommended that the vaccine only
be used in people who have previously had a dengue infection, as
outcomes may be worsened in those who have not been previously
infected.
Fact 5: The World Health Organization (WHO) recommends that
countries should consider vaccination with the dengue vaccine only if
the risk of severe dengue in seronegative individuals can be minimized.
In September 2018, WHO updated its recommendation based on the
evidence that seronegative vaccine recipients have an excess risk of
severe dengue compared to unvaccinated seronegative individuals.
Fact 6: More than 733,000 children and more than 50,000 adult volunteers were vaccinated with dengue
vaccine in the Philippines. Some who received the vaccine had never been infected by the dengue virus
before.
Fact 7: It is still unknown if Sanofi did not inform the Philippine government of the precautions or that the
Phil government and doctors neglected to implement necessary precautions such as sero-testing before
vaccination.
Fact 8: Some claims that children who were vaccinated with the Dengvaxia died due to complications
caused by the vaccine. As of now, investigations and judicial trial is on progress.
Fact 9: No controversy on the dengvaxia vaccines in other countries where it was approved.
Transcribed Image Text:Terms: Seronegative: Individuals who had never been infected by dengue virus. Fact 1: The program on the study for the production of dengue vaccine started in 1920. Vaccines are usually produced with minimum of 5 years of clinical trials. Fact 2: Dengvaxia, a dengue vaccine produced by Sanofi Pharmaceuticals, became commercially available in 2015 and 2016, in 11 countries: Mexico, the Philippines, Indonesia, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Thailand, and Singapore. Fact 3: Trade named Dengvaxia, it is approved for use for those aged nine and older and can prevent all four serotypes resulting from high efficacy rate in its trial use. Fact 4: In 2017, the manufacturer recommended that the vaccine only be used in people who have previously had a dengue infection, as outcomes may be worsened in those who have not been previously infected. Fact 5: The World Health Organization (WHO) recommends that countries should consider vaccination with the dengue vaccine only if the risk of severe dengue in seronegative individuals can be minimized. In September 2018, WHO updated its recommendation based on the evidence that seronegative vaccine recipients have an excess risk of severe dengue compared to unvaccinated seronegative individuals. Fact 6: More than 733,000 children and more than 50,000 adult volunteers were vaccinated with dengue vaccine in the Philippines. Some who received the vaccine had never been infected by the dengue virus before. Fact 7: It is still unknown if Sanofi did not inform the Philippine government of the precautions or that the Phil government and doctors neglected to implement necessary precautions such as sero-testing before vaccination. Fact 8: Some claims that children who were vaccinated with the Dengvaxia died due to complications caused by the vaccine. As of now, investigations and judicial trial is on progress. Fact 9: No controversy on the dengvaxia vaccines in other countries where it was approved.
Expert Solution
steps

Step by step

Solved in 3 steps

Blurred answer
Knowledge Booster
Immune disorders
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, biology and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
An Illustrated Guide To Vet Med Term
An Illustrated Guide To Vet Med Term
Biology
ISBN:
9781305465763
Author:
ROMICH
Publisher:
Cengage
Biomedical Instrumentation Systems
Biomedical Instrumentation Systems
Chemistry
ISBN:
9781133478294
Author:
Chatterjee
Publisher:
Cengage
Case Studies In Health Information Management
Case Studies In Health Information Management
Biology
ISBN:
9781337676908
Author:
SCHNERING
Publisher:
Cengage
Nutrition Now
Nutrition Now
Health & Nutrition
ISBN:
9781337415408
Author:
Brown
Publisher:
Cengage
Basic Clinical Laboratory Techniques 6E
Basic Clinical Laboratory Techniques 6E
Biology
ISBN:
9781133893943
Author:
ESTRIDGE
Publisher:
Cengage
Comprehensive Medical Assisting: Administrative a…
Comprehensive Medical Assisting: Administrative a…
Nursing
ISBN:
9781305964792
Author:
Wilburta Q. Lindh, Carol D. Tamparo, Barbara M. Dahl, Julie Morris, Cindy Correa
Publisher:
Cengage Learning